$TYRA

TYRA SEC Filings - Tyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Tyra Biosciences SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material event forms, and insider trading forms. Tyra Biosciences is a clinical-stage biotechnology company focusing on precision medicines. The site offers AI-powered summaries to highlight key disclosures, clinical trial milestones, and financial commentary.

Original reporting
Published Apr 30, 2026, 2:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 30, 2026, 7:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TYRA
Neutral
medium confidence
Mentioned
$TYRA
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$TYRANeutralLow
01

Why it matters

The SEC filings reaffirm the company's progress but do not indicate immediate catalysts for stock movement.

02

Market read

The filings are relevant for long-term investors and biotech sector analysts, with limited short-term trading impact.

03

What to watch

Potential regulatory changes or partnership announcements could significantly impact stock performance.

Timing: long-term

Background

Tyra Biosciences is a clinical-stage biotech focusing on precision medicines, with ongoing trials and financial stability.

Company-level read

Ticker impact

$TYRANeutralMedium confidence
Context

The SEC filings provide detailed insights into Tyra Biosciences' financial health, clinical milestones, and strategic direction, which are crucial for assessing long-term investment potential.

Expected impact

Limited immediate price movement expected; potential for upward trend if clinical milestones are met.

Evidence & confidence

The filings contain positive indicators but lack significant new data that could trigger immediate trading actions.

Market effects

Positive developments in biotech sector, especially for clinical-stage biotech companies.

Minimal regional impact; company operations are primarily US-focused.

Limited; company is a smaller player with niche focus.

Counterpoint

The neutral tone suggests limited immediate upside; some investors may prefer to wait for more definitive clinical success before increasing exposure.

Key entities

  • Tyra Biosciences, Inc.

    A biotech company specializing in precision medicines, currently in clinical development.

Related articles

$TYRAHighAI 8/10

Why Is Tyra Biosciences Stock Sinking Wednesday? - Tyra Biosciences (NASDAQ:TYRA)

Tyra Biosciences (NASDAQ:TYRA) shares fell 21.6% after Phase 2 trial results for dabogratinib showed an 86% overall response rate in patients with target exposure, but a 57% complete response rate at 60 mg, below analyst expectations of 70-80%. The company plans to advance to Phase 3 development and expand the study to a 70 mg cohort. Initial upper tract urothelial cancer study results were positive.

$TYRAHighAI 8/10

Why is Tyra Biosciences stock plunging today?

Tyra Biosciences (TYRA) stock fell 31.1% to $18.42 after Phase 2 trial results for dabogratinib showed a 64% complete response rate, below the 70% analyst consensus. Piper Sandler and H.C. Wainwright had modeled a 70% rate as the success threshold. The stock had risen 13% the prior week. Broader market caution added to the decline.

$TYRAHighAI 9/10

Tyra Biosciences stock tumbles 30% on phase 2 trial results

Tyra Biosciences (NASDAQ: TYRA) shares dropped 30% after reporting Phase 2 trial results for dabogratinib. The drug showed a 79% overall response rate and 64% complete response rate in combined patients. The trial enrolled 44 participants, with safety results indicating low rates of severe adverse events. Tyra plans to continue enrollment and engage with health authorities for Phase 3 study design.

$TYRAMed

Piper Sandler reiterates Tyra Biosciences stock rating ahead of data

Piper Sandler reiterated an Overweight rating and $56 price target for Tyra Biosciences (NASDAQ: TYRA) ahead of clinical trial data. The stock has risen 13% in a week and 136% in a year, trading at $28.60. Piper Sandler expects a 70% response rate for dabogratinib in bladder cancer trials, which could advance the drug to Phase 3. The firm sees a $1B+ opportunity in this market. Other analysts also maintain Buy ratings with targets up to $45.